Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| ABBOTT LABORATORIESABT · Entity 2314 | SENIOR VICE PRESIDENT | February 28, 2023 | March 03, 2023 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
ABBOTT LABORATORIES
Report date February 28, 2023 · Filed March 03, 2023
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common shares without par valueSEC Table I · non-derivative | Direct | 71,366 |
Ending reported balance
After 2023-03-01 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2023-02-28 · Tax withholding · Disposed 5,598 · Balance 72,564 Row 2 · 2023-03-01 · Sale · Disposed 1,198 · Balance 71,366 |
| Common shares without par valueSEC Table I · non-derivative | IndirectProfit Sharing Trust | 652 |
Reported balance
Holding disclosure · report date 2023-02-28 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 652 F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023. |
Filing footnotes · ownership attribution and instrument terms
F1: Balance in the Abbott Laboratories Stock Retirement Trust as of February 28, 2023.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 20, 2018 Filed Feb 21, 2018 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 683 | $60.17 | $41,096.11 |
DisclosureSEC source: 0001179110-18-002514 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 73,674 Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 152,981 | $0.00 Strike: $59.94 | $0.00 |
DisclosureSEC source: 0001179110-18-002514 · edgar.xml · derivative · entry 6 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 152,981 Underlying: Common shares · 152,981 shares Expires 2028-02-15 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 50,994 on 02/16/2019, 50,993 on 02/16/2020, and 50,994 on 02/16/2021. Read SEC document |
| February 16, 2018 Filed Feb 21, 2018 23:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 27,819 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-18-002514 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 74,357 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2017 Incentive Stock Program. The awards have a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $47.98 | $14,392.50 |
DisclosureSEC source: 0001179110-17-009206 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,538 Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 152 | $47.97 | $7,291.59 |
DisclosureSEC source: 0001179110-17-009206 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,838 Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $47.98 | $4,798.10 |
DisclosureSEC source: 0001179110-17-009206 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,990 Read SEC document |
| June 15, 2017 Filed Jun 16, 2017 21:02 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,421 | $47.64 | $67,696.44 |
DisclosureSEC source: 0001179110-17-009206 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,090 Read SEC document |
| March 01, 2017 Filed Mar 2, 2017 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 970 | $45.39 | $44,028.30 |
DisclosureSEC source: 0001179110-17-003676 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,511 Read SEC document |
| February 28, 2017 Filed Mar 2, 2017 22:12 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 2,496 | $45.46 | $113,468.16 |
DisclosureSEC source: 0001179110-17-003676 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,481 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 55 | $44.99 | $2,474.29 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 7 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,977 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $44.99 | $4,498.50 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 6 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,032 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 100 | $44.98 | $4,498.10 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 5 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,132 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 300 | $44.98 | $13,494.00 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,232 Read SEC document |
| February 21, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 683 | $44.69 | $30,523.27 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 52,532 Read SEC document |
| February 20, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 740 | $44.69 | $33,070.60 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,215 Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 51,129 | $0.00 Strike: $44.40 | $0.00 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · derivative · entry 9 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 51,129 Underlying: Common shares · 51,129 shares Expires 2027-02-16 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 17,043 on 02/17/2018, 17,043 on 02/17/2019, and 17,043 on 02/17/2020. Read SEC document |
| February 17, 2017 Filed Feb 22, 2017 22:57 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 7,393 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-17-002951 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 53,955 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| June 15, 2016 Filed Jun 17, 2016 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 552 | $37.63 | $20,770.10 |
DisclosureSEC source: 0001179110-16-026633 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 46,562 Read SEC document |
| June 15, 2016 Filed Jun 17, 2016 21:05 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 1,421 | $37.66 | $53,514.86 |
DisclosureSEC source: 0001179110-16-026633 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,114 Read SEC document |
| February 22, 2016 Filed Feb 23, 2016 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 154 | $39.09 | $6,020.48 |
DisclosureSEC source: 0001179110-16-019885 · edgar.xml · nonDerivative · entry 5 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,535 Read SEC document |
| February 22, 2016 Filed Feb 23, 2016 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 400 | $39.10 | $15,638.00 |
DisclosureSEC source: 0001179110-16-019885 · edgar.xml · nonDerivative · entry 4 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 48,689 Read SEC document |
| February 21, 2016 Filed Feb 23, 2016 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 683 | $38.53 | $26,315.99 |
DisclosureSEC source: 0001179110-16-019885 · edgar.xml · nonDerivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,089 Read SEC document |
| February 20, 2016 Filed Feb 23, 2016 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 743 | $38.53 | $28,627.79 |
DisclosureSEC source: 0001179110-16-019885 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,772 Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 174,657 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-16-019885 · edgar.xml · derivative · entry 7 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 174,657 Underlying: Common shares · 174,657 shares Expires 2026-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 58,219 on 02/19/2017, 58,219 on 02/19/2018, and 58,219 on 02/19/2019. Read SEC document |
| February 19, 2016 Filed Feb 23, 2016 22:38 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 19,921 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-16-019885 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,515 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
| February 16, 2016 Filed Feb 17, 2016 22:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | SaleCommon shares without par value | 207 | $37.13 | $7,685.91 |
DisclosureSEC source: 0001179110-16-019499 · edgar.xml · nonDerivative · entry 2 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,594 Read SEC document |
| February 15, 2016 Filed Feb 17, 2016 22:44 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | Tax withholdingCommon shares without par value | 606 | $37.13 | $22,500.78 |
DisclosureSEC source: 0001179110-16-019499 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 30,801 Read SEC document |
| June 15, 2015 Filed Jun 16, 2015 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantOption (right to buy) · Derivative | 114,692 | $0.00 Strike: $48.04 | $0.00 |
DisclosureSEC source: 0001179110-15-009924 · edgar.xml · derivative · entry 3 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 114,692 Underlying: Common shares · 114,692 shares Expires 2025-06-14 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 38,231 on 06/15/2016, 38,230 on 06/15/2017, and 38,231 on 06/15/2018. Read SEC document |
| June 15, 2015 Filed Jun 16, 2015 22:21 UTC | ABBOTT LABORATORIES ABT · Entity 2314 | GrantCommon shares without par value | 11,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001179110-15-009924 · edgar.xml · nonDerivative · entry 1 Watkin Jared · CIK 0001645118 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 31,407 F1 · shares: These shares represent performance vested restricted stock awards under the Abbott Laboratories 2009 Incentive Stock Program. The awards have a 5-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The awards include the right to have stock withheld for tax purposes. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.